Loading patent…
AssigneesBiocon Limited, Centro De Inmunologia Molecular
InventorsRAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
Estimating the term…
The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
A method of inhibiting naïve T cell proliferation, the method comprising administering a therapeutically effective amount of a monoclonal anti-CD6 antibody that binds to domain 1(D1) of CD6 without interfering with ALCAM binding, wherein the monoclonal antibody comprises heavy and light chain variable regions comprising amino acid sequences as set forth in SEQ ID NOs:
A method of treatment for an inflammatory disorder, the method comprising administering to a patient a therapeutically effective amount of a monoclonal anti-CD6 antibody that binds to domain 1 (D1) of CD6 without interfering with ALCAM binding, wherein the monoclonal antibody comprises heavy and light chain variable regions comprising amino acid sequences as set forth in SEQ ID NOs:
Dependencies are inferred from the claim text.